FDMT (STOCKS)
4D Molecular Therapeutics, Inc. Common Stock
$9.250000
+0.150000 (+1.65%)
Prev close: $9.100000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David H. Kirn
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $477.60M
- Employees
- 227
- P/E (TTM)
- -2.35
- P/B (TTM)
- 1.15
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $120.00K |
| Benefits Costs and Expenses | $97.66M |
| Costs And Expenses | $218.40M |
| Nonoperating Income/Loss | $21.20M |
| Operating Expenses | $230.50M |
| Depreciation and Amortization | $4.57M |
| Other Operating Expenses | $225.93M |
| Operating Income/Loss | -$230.38M |
| Income/Loss From Continuing Operations After Tax | -$209.18M |
| Income/Loss From Continuing Operations Before Tax | -$152.21M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$209.18M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$209.18M |
| Net Income/Loss Available To Common Stockholders, Basic | -$209.18M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.75 |
| Diluted Earnings Per Share | -$3.75 |
| Basic Average Shares | 168,363,497 |
| Diluted Average Shares | 168,363,497 |
| Assets | $423.98M |
| Current Assets | $312.38M |
| Noncurrent Assets | $111.61M |
| Fixed Assets | $16.15M |
| Other Non-current Assets | $95.45M |
| Liabilities | $55.00M |
| Current Liabilities | $37.11M |
| Accounts Payable | $6.86M |
| Wages | $9.12M |
| Other Current Liabilities | $21.12M |
| Noncurrent Liabilities | $17.89M |
| Equity | $368.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $368.98M |
| Liabilities And Equity | $423.98M |
| Net Cash Flow From Operating Activities | -$183.50M |
| Net Cash Flow From Operating Activities, Continuing | -$183.50M |
| Net Cash Flow From Investing Activities | $42.93M |
| Net Cash Flow From Investing Activities, Continuing | $42.93M |
| Net Cash Flow From Financing Activities | $1.58M |
| Net Cash Flow From Financing Activities, Continuing | $1.58M |
| Net Cash Flow | -$138.98M |
| Net Cash Flow, Continuing | -$138.98M |
| Comprehensive Income/Loss | -$209.69M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$209.59M |
| Other Comprehensive Income/Loss | -$57.39M |